This website is intended for healthcare professionals

Lecanemab

NICE rejects new Alzheimer's treatment citing ‘significant costs’ to the NHS

UK’s drug regulator gave the green light for the drug, but NICE rejected it as the benefits ‘are too small to justify the costs’

Why choose British Journal of Nursing?

BJN provides nurses with an evidence base for clinical practice and a platform for professional development. It shares the information and advice that is key to unlocking your full potential.

What's included

  • Clinical expertise

  • Peer-reviewed research

  • Best practice guidance

  • CPD support

Subscriptions start:

From £13.75 GBP